课题基金 / 基金详情

项目摘要

项目成果

Eva M. Sevick-Muraca的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Core #1 Chemistry Dr. Wei Wang, Ph.D. The Chemistry core functions in the Division of Molecular Imaging and in this NTR consortium to (i) provide the ability to develop new molecularly targeting entities for both nuclear and optical imaging; (ii) develop the validated analytical tools necessary for new agents; and (iii) provide assistance in manufacture. New targeting entities Dr. Wei Wang's expertise and demonstrated innovation is evident in the small animal imaging results presented in Section 5.C.4,5 regarding the c(KRGD) and c(KAHWGFLD) dual labeled imaging agents. The following provides an example of her emerging work with Dr. Charles Brunicardi to develop an optical substrate for imaging vTK gene expression. [18F]-FHBG and other isotope substrates have been used along with several other TK substrates [143-145]. Although [18F]-FHBG is currently approved as an investigational drug for human studies [146], its short half life (2 h) may be responsible for the high background in small animal imaging. For example, in studies to track vTK expressing tumor cells, investigators routinely use subcutaneous tumor implantation on the shoulder of animals. One hour after administration, incomplete clearance prevents distinguishing tumor cells within the trunk of the animal. In addition, isotopically labeled agents are not widely available to the biomedical research community. For this reason, Dr. Wei Wang developed three optical analogs of FHBG depicted in Fig. 43 that are conjugated to NIR dye IR783 that is synthesized in-house. It is noteworthy that the second compound, could be developed as a potential dual labeled PET and optical imaging agent by replacing cold fluorine with 18F.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessing CSF flow dynamics in pediatric hemorrhagic hydrocephalus
Lymphatic delivery of immunotherapy to prevent irAEs
Assessing CSF flow dynamics in pediatric hemorrhagic hydrocephalus
Lymphatic delivery of immunotherapy to prevent irAEs
海外基金